Display Settings:

Format

Send to:

Choose Destination
    Nat Rev Rheumatol. 2009 Jun;5(6):304-5.

    Connective tissue diseases: The conundrum of B cell depletion in SLE.

    Abstract

    Two consecutive trials of rituximab, a B-cell-depleting anti-CD20 monoclonal antibody, have threatened the future of B-cell-targeted therapy for systemic lupus erythematosus (SLE). While rumors of the demise of this approach might be greatly exaggerated, the outcomes of these studies should force academics and the pharmaceutical industry back to the drawing board.

    PMID:
    19491910
    [PubMed - indexed for MEDLINE]

      Supplemental Content

      Click here to read

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk